Biotinylated Human HLA-A*02:01&B2M&p53 (RMPEAAPPV) Complex Protein (Monomer, MALS verified)

TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (GLAPPQHLIRV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and GLAPPQHLIRV peptide of the p53.

Biotinylated Human HLA-A*02:01&B2M&p53 (RMPEAAPPV) Complex Protein is produced by co-expression of HLA and B2M loaded with p53 peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-43 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Biotinylated Human HLA-A*02:01&B2M&p53 (RMPEAAPPV) Complex Protein (Cat. No. HLP-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-2 ng/mL (QC tested).